机构:[1]Medical Faculty of Kunming University of Science and Technology, Kunming 650500, China.[2]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.[3]Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.[4]College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China.[5]Translational Cancer Research Center, Peking University First Hospital, Beijing, 100034, China.[6]KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.[7]Institute of Translation Medicine, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.深圳市第二人民医院深圳医学信息中心
As the most malignant subtype of breast cancers, triple-negative breast cancer (TNBC) lacks effective targeted therapeutics clinically to date. In this study, one lead compound FZU-0025-065 with isochromanoindolenine scaffold was identified by a cell-based screening. Among nine breast cancer cell lines tested, TNBC are the most sensitive cell lines to FZU-0025-065. FZU-0025-065 inhibits TNBC cell growth in a time- and dosage-dependent manner. FZU-0025-065 suppresses the expression of cell cycle dependent kinase 4 (CDK4), Cyclin D1 and Cyclin B1; meanwhile, elevates the expression of cell cycle dependent kinase inhibitor p21 and p27. Importantly, we found that FZU-0025-065 suppresses AKT activation in a time- and dosage-dependent manner. Over-expression of constitutive active AKT partially rescues FZU-0025-065 induced cell growth inhibition in MDA-MB-468 cells, indicating FZU-0025-065 suppresses TNBC cell growth partially via inhibiting AKT activation. Finally, FZU-0025-065 suppresses TNBC cell growth in a xenograft mouse model. Taken together, our findings suggested that isochromanoindolenine derivative FZU-0025-065 inhibits TNBC via suppressing the AKT signaling and that FZU-0025-065 may be useful for TNBC treatment.
基金:
National Key Research and Development Program of
China [2020YFA0112300 and 2018YFC2000400 to C.
Chen], National Natural Science Foundation of China
[81830087 and 31771516 to C. Chen; 81772847 and
82073270 to R. Liu; 81971440 and 81671458 to X. Zhi],
Project of Innovative Research Team of Yunnan
Province [2019HC005], and the Natural Science
Foundation of Fujian Province [2019J01202 to H.
Chen].
第一作者机构:[1]Medical Faculty of Kunming University of Science and Technology, Kunming 650500, China.[2]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.
共同第一作者:
通讯作者:
通讯机构:[2]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.[5]Translational Cancer Research Center, Peking University First Hospital, Beijing, 100034, China.[6]KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.[7]Institute of Translation Medicine, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.
推荐引用方式(GB/T 7714):
Xiaoyan Jiang,Xu Zhi,Peixia Zhang,et al.Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation[J].INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES.2021,17(4):986-994.doi:10.7150/ijbs.48170.
APA:
Xiaoyan Jiang,Xu Zhi,Peixia Zhang,Zhongmei Zhou,Jinxiang Ye...&Ceshi Chen.(2021).Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation.INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES,17,(4)
MLA:
Xiaoyan Jiang,et al."Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation".INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 17..4(2021):986-994